Trump administration indefinitely delayed BALANCE, a Medicare pilot to expand GLP-1 weight-loss drug coverage through private insurers, Axios reports

The indefinite delay of the BALANCE Medicare pilot program impacts the coverage of GLP-1 weight-loss drugs, reflected through a transitional program instead.

Newsquawk StaffPublished On the live feed at 5 more headlines followed before this page went public
Newsquawk headlinesUTC

Newsquawk Daily US Opening News - 22nd April 2026

Exxon (XOM) is mulling sale of its gas stations in Hong Kong, Bloomberg reports

Trump administration indefinitely delayed BALANCE, a Medicare pilot to expand GLP-1 weight-loss drug coverage through private insurers, Axios reports

Germany sells EUR 1.96bln vs exp. EUR 2bln 2.60% 2041 and 3.40% 2047 Bunds

Sandvik (SAND SS) Q1 2026 (SEK): Adj. EPS 3.09 (exp. 3.26), revenue SEK 30.7bln (exp. 31.3bln)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • Medicare will instead cover the drugs through a transitional programme from July until the end of 2027
  • UnitedHealth (UNH), Eli Lilly (LLY), Novo Nordisk (NOVOB DC) and AHIP were cited around insurer concerns, beneficiary access and next steps
Context

This could create uncertainty for insurers like UnitedHealth and pharmaceutical companies such as Eli Lilly and Novo Nordisk regarding revenue projections and market access. The regulatory landscape here may influence broader health care funding and investment strategies across the sector.

Related headlines

The whole workspace, free to try.

Try it free